


ACEM Primary Examination Vivas > Pharmacology > General		
Organised by edvivas.com		
Miscellaneous	Drugs and the Elderly 2017-2-C	4
Miscellaneous	Drugs and the Elderly 2013-1	5
Miscellaneous	Drugs and the Elderly 2009-1	6
Miscellaneous	Drugs and the Elderly 2006-2	7
Miscellaneous	Drugs and the Elderly 2004-2	8
Miscellaneous	Drugs in Children 2009-1	9
Miscellaneous	Drugs in Pregnancy 2009-1	10
Miscellaneous	Variations in Drug levels 2010-1	11
Miscellaneous	Variations in Drug Response 2005-1	12
Pharmacodynamics	Agonists 2012-1	13
Pharmacodynamics	Agonists 2011-2	14
Pharmacodynamics	Antagonists 2013-2-D	15
Pharmacodynamics	Antagonists 2011-2	16
Pharmacodynamics	Antagonists 2010-1	17
Pharmacodynamics	Antagonists 2008-1	18
Pharmacodynamics	Antagonists 2003-2	19
Pharmacodynamics	Efficacy and Potency 2017-1-A	20
Pharmacodynamics	Efficacy and Potency 2013-1	21
Pharmacodynamics	Efficacy and Potency 2010-2	22
Pharmacodynamics	Efficacy and Potency 2008-2	23
Pharmacodynamics	Efficacy and Potency 2007-1	24
Pharmacodynamics	Efficacy and Potency 2006-1	25
Pharmacodynamics	Efficacy and Potency 2005-1	26
Pharmacodynamics	Second Messengers 2010-1	27
Pharmacodynamics	Second Messengers 2008-1	28
Pharmacodynamics	Second Messengers 2006-2	29
Pharmacodynamics	Second Messengers 2004-2	30
Pharmacodynamics	Second Messengers 2003-2	31
Pharmacodynamics	Signalling Mechanisms 2012-2	32
Pharmacodynamics	Spare Receptors 2010-1	33
Pharmacodynamics	Spare Receptors 2009-2	34

Better Than WHISKEY for Colds and Flu

DELIGHTFUL ELIXIR, CALLED ASPIRONAL, MEDICATED WITH LATEST SCIENTIFIC REMEDIES THAT ARE ENDORSED BY MEDICAL AUTHORITIES TO CUT SHORT A COLD OR COUGH DUE TO COLD AND PREVENT COMPLICATIONS.

Every Druggist in U. S. Instructed to Refund Price While You Wait at Counter if You Don't Feel Relief Coming in Two Minutes.

DELIGHTFUL TASTE, IMMEDIATE RELIEF, QUICK WARM-UP.



The sensation of the drug trade is Aspironal, the two-minute cold and cough reliever, authoritatively guaranteed by the laboratories; tested, approved and most enthusiastically endorsed by the people as ten times as quick and effective as whiskey, rock and rye, or any other cold and cough remedy they have ever tried.

When your cold or cough is relieved, take the remainder of the bottle home to your wife and children, for Aspironal is by far the safest and most effective, the easiest to take and the most agreeable cold and cough remedy for children as well as adults. Quickest relief for catarrhal croup and children's choking up at night.

**Don't Let That Cold Run Into Something Worse--
Stop it Now With
ASPIRONAL**

Pharmacodynamics	Spare Receptors 2006-2	35
Pharmacokinetics	Absorption 2011-1	36
Pharmacokinetics	Absorption 2005-2	37
Pharmacokinetics	Bioavailability 2014-1-D	38
Pharmacokinetics	Bioavailability 2013-1	39
Pharmacokinetics	Bioavailability 2011-2	40
Pharmacokinetics	Bioavailability 2008-1	41
Pharmacokinetics	Bioavailability 2005-1	42
Pharmacokinetics	Bioavailability 2003-2	43
Pharmacokinetics	Biotransformation 2014-2-D	44
Pharmacokinetics	Biotransformation 2012-2	45
Pharmacokinetics	Biotransformation 2012-1	46
Pharmacokinetics	Biotransformation 2011-1	47
Pharmacokinetics	Biotransformation 2009-2	48
Pharmacokinetics	Biotransformation 2005-2	49
Pharmacokinetics	Biotransformation 2003-1	50
Pharmacokinetics	Clearance 2017-2-C	51
Pharmacokinetics	Clearance 2014-1-D	52
Pharmacokinetics	Clearance 2012-2	53
Pharmacokinetics	Clearance 2010-2	54
Pharmacokinetics	Clearance 2009-2	55
Pharmacokinetics	Clearance 2005-2	56
Pharmacokinetics	CYP 450 2008-2	57
Pharmacokinetics	CYP 450 2007-2	58
Pharmacokinetics	Elimination 2013-2-D	59
Pharmacokinetics	Elimination 2012-1	60
Pharmacokinetics	Elimination 2009-1	61
Pharmacokinetics	Elimination 2006-1	62
Pharmacokinetics	First Pass Effect 2010-2	63
Pharmacokinetics	First Pass Effect 2008-2	64
Pharmacokinetics	First Pass Effect 2007-2	65
Pharmacokinetics	Half life 2009-1	66
Pharmacokinetics	Half life 2006-2	67
Pharmacokinetics	Phase 1 and Phase 1 Reactions 2007-1	68

Pharmacokinetics	Routes of Administration 2007-2	69
Pharmacokinetics	Volume of Distribution 2012-2	70
Pharmacokinetics	Volume of Distribution 2011-1	71
Pharmacokinetics	Volume of Distribution 2009-1	72
Pharmacokinetics	Volume of Distribution 2007-1	73
Pharmacokinetics	Volume of Distribution 2006-1	74
Pharmacokinetics	Volume of Distribution 2003-1	75

4

Drugs and the Elderly 2013-1

TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1: PHARMACOKINETICS LOA: 2	Describe the pharmacokinetic changes that occur in the elderly	Absorption: nutritional deficits; delayed gastric emptying (diabetics); co ingested agents (laxatives, antacids) Distribution: ↑ body fat, alpha-acid glycoprotein (bases); ↓ lean body mass, body water, albumin (weak acids); Metabolism: ↓ phase 1 reactions P450; ↓ liver blood flow, liver disease, CCF, nutritional defic Elimination: ↓ renal CL; renal disease; ↓ resp capacity; resp disease	Hepatic metabolism↓ Renal clearance↓ + 1 other

Drugs and the Elderly 2009-1

<p>Question 5: Prescribing in the Elderly</p>	<p>1. In the elderly, what factors change with age and alter pharmacokinetics.</p>	<p>Absorption: No major change unless additional underlying associated condition with age Distribution: Dec lean body mass, Dec body water %, Inc fat body %, Dec serum albumin, Dec apparent Vd and sometimes increased Vd Metabolism: Liver metabolism does not decline for all drugs, Dec liver blood flow, Dec phase 1 > phase 2 reactions, Liver slower to recover from injury Elimination: Dec renal function & Cr clearance, Half life inc of drugs variable, Dec excretion of volatile substances by the lung Associated age related illness affecting any of the above</p>	<p>Pass: renal function, 2 factors that may change Vd,</p>
	<p>2. Give some examples of drugs commonly used in the emergency department that must have their prescribing altered in the elderly?</p>	<p>Benzodiazepines – liver metabolism, renal function; PD sensitivity Opioids –PD sensitivity respiratory effects Antipsychotics –PD sensitivity; lean body mass NSAID – GI, renal Colchicine –renal, narrow therapeutic index Other drugs narrow therapeutic index Drugs primarily excreted renally –gentamicin, acyclovir Digoxin loading dose with dec Vd Amiodarone loading – Vd and PD sensitivity Many drugs as polypharmacy and must check for interactions i.e. Warfarin. So could argue extra precautions with all –polypharmacy, increase risk of error, compliance and administration issues Interactions with age related disease – IHD, COPD (B agonists or B Blockers) Sulphurs/Bactrim –adverse reactions Anticoagulants – falls Drugs which switch to zero order kinetics -phenytoin</p>	<p>Must get 4 relevant and plausible examples with correct associated mechanism & must include benzos and opioids.</p> <p>Prompts:</p> <ul style="list-style-type: none"> • What about commonly used intravenous agents in the ED? • What about analgesic agents used in the ED? • What about sedative agents used in the ED? • Are there any drugs to be reduced with impaired renal function?

Drugs and the Elderly 2006-2

5. PK in elderly	What factors affect drug distribution in the elderly? (3 FOR A PASS) Give examples of drugs where hepatic clearance does not change with age (BONUS)	Reduced lean body mass, Reduced body water (total and %), Increase in body fat (%), Decreased serum albumin, Overall a decreased apparent volume of distribution Salicylate, Warfarin, Ethanol, Oxazepam, Nitrazepam, Lignocaine, Prazosin	
-------------------------	---	---	--

Drugs and the Elderly 2004-2

Pharmacokinetics in the elderly	<p>Outline the changes in pharmacokinetics that occur in the elderly</p> <p>How does the pharmacokinetics of gentamycin change in the elderly ?</p>	<p>Cover 2 of 4 with description - absorption, distribution, metabolism, excretion</p> <p>Decreased renal excretion increases half life</p>	
---------------------------------	---	---	--

Drugs in Children 2009-1

<p>Question 5 Prescribing in children</p>	<p>1. In children, what factors change with age and alter pharmacokinetics?</p>	<p>Body Size and Composition – Growth of child – most doses calculated in mg/kg Adult is 50% water 20% extracellular Term neonate 70-75% water 40% extracellular Pre term neonate 85% water Influences drugs distributed in extra cellular space</p> <p>Fat 15% in adults 1% in pre term infants</p> <p>Plasma proteins Albumin – Decreased levels in neonate Potential for increased toxicity in neonates if drugs are highly protein bound Jaundiced neonates – if drug highly protein bound, will displace bilirubin and cause kernicterus</p> <p>Drug Metabolism Most drugs metabolised in liver Only 50-70% of adult values Slow clearance and prolonged elimination half lives</p> <p>Drug excretion GFR lower in newborns than older infants Neonate 30-40% adult values 3 weeks 50-60 % adult values 6-12 months Adult values</p>	<p>Pass: body size and composition, and drug metabolism and excretion.</p>
---	---	--	--

Drugs in Pregnancy 2009-1

Question 5: Prescribing in Pregnancy	1. List the factors affecting placental drug transfer?	Lipid solubility Molecular size Placental transporters Protein binding Placental and foetal drug metabolism	Pass: 2 of 5
	2. What is meant by foetal therapeutics?	Drug administration to the pregnant woman with the foetus as the target	
	3. Give examples of drugs administered for this purpose?	Corticosteroids (for lung maturation) Phenobarbitone (induce enzymes for glucuronidation of bilirubin) Antiretrovirals (decrease HIV transmission) Antiarrhythmics	

Variations in Drug levels 2010-1

<p>Question 5: Therapeutic drug monitoring p46-49</p>	<p>1. What pharmacokinetic variables affect drug levels?</p> <p><i>Patient factors?</i></p> <p><i>Specific drug examples?</i></p> <p>2. What pharmacodynamic variables affect drug dosing?</p>	<p>absorption – eg small bowel abnormalities clearance – eg impaired renal, liver, cardiac function volume of distribution – changes in either tissue or plasma binding impact drug availability; eg decreased muscle mass in elderly, hypoalbuminaemia, drug interaction.</p> <p>maximum effect (Emax) – vs toxicity by increasing dosing beyond maximum effect sensitivity (EC50) – eg hyperkalemia decreases sensitivity to and effect of digoxin</p>	<p>2 variables</p>
---	--	--	--------------------


Variations in Drug Response 2005-1

<p>Variation in drug response.</p>	<p>List the factors which contribute to the variation in the response to a drug .</p> <p>Prompt: What mechanisms are involved?</p>	<ul style="list-style-type: none"> • Factors include: <ul style="list-style-type: none"> – Age – Gender – Body mass – Disease states – Other drugs coadministered • Also: tolerance, tachyphylaxis, idiosyncratic reaction. <p>(3 of 5)</p> <p>4 general mechanisms.</p> <ol style="list-style-type: none"> Alteration in concentration of drug that reaches receptor . (eg altered absorption, altered clearance) Variation in concentration of an endogenous receptor ligand. (eg propranolol in patients with elevated vs. normal endogenous catecholamines) Alteration in the number or function of receptors (eg. down regulation → tolerance, overshoot → withdrawal) Changes in response components distal to the receptor (eg. age, health, disease) <p>(2 of 4)</p>	
---	--	---	--

Agonists 2012-1


TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1 LOA: 1 PARTIAL AGONIST	<p>In the context of drug-receptor interactions, what is the difference between a full agonist and a partial agonist?</p> <p>Under what circumstances can a partial agonist act as a antagonist? <i>Prompt: Can you use opioids as an example?</i></p>	<p>High concentrations of full agonists can evoke a maximal response, but partial agonists cannot evoke maximal response at any concentration</p> <p>In the presence of a full agonist Buprenorphine</p>	

Agonists 2011-2

<p>Question 1</p> <p>Drug concentration and response</p>	<p>a) In relation to drug concentration and responses, what is the EC50?</p> <p>b) What are spare receptors?</p>	<p>a) EC50 is the concentration at which an agonist produces half its maximal effect.</p> <p>b) Need to understand concept of spare receptors. The concentration of agonist producing a maximum response may not result in occupancy of full complement of receptors. These receptors are said to be "spare." Temporal or in number</p> <p>Dose-response curve for irreversible antagonist.</p>  <p>A = no antagonist B = low dose antagonist. Still get maximum effect because receptors still in excess of required for effect C = Largest concentration of antagonist to produce maximum effect. Therefore no spare receptors. D + E = high concentrations of antagonist which diminish maximum response</p>	<p>Good understanding of bolded</p>
--	--	--	-------------------------------------

Antagonists 2013-2-D

Stem: A 30 year old man has had a motor vehicle accident after a heroin overdose, and has been given Naloxone. Commencing with Pharmacology:

TOPIC	QUESTIONS	KNOWLEDGE	NOTES
PHARMACOLOGY Question 1 LOA: 1	1. What is an antagonist? What type of antagonist is naloxone? 3. What effect does a competitive antagonist have on the concentration-effect curve?	1. Receptor antagonists bind to receptors but do not activate them. The primary action of antagonists is to prevent agonists from activating receptors . 2. Competitive antagonist: In the presence of increasing concentration of antagonist, higher concentrations of agonist will produce a given effect . Eg propranolol and noradrenaline / adrenaline. Irreversible or non competitive antagonist Bind via covalent bonds or just binding so tightly to receptor so receptor unavailable for agonist. Duration of action of antagonist depend on rate of turnover of receptor-antagonist molecules. Competitive 3. Shift agonist vs effect curve to right. Higher concentrations of agonist can overcome competitive antagonist	Bold to pass
			

Antagonists 2011-2

<p>Question 1</p> <p>Competitive and non-competitive antagonists</p>	<p>a) What is an antagonist?</p> <p>b) What is the difference between a competitive and non-competitive antagonist?</p>	<p>a) Receptor antagonists bind to receptors but do not activate them. The primary action of antagonists is to prevent agonists from activating receptors.</p> <p>b) <u>Competitive antagonist</u> In the presence of increasing concentration of antagonist, higher concentrations of agonist will produce a given effect. Eg propranolol and noradrenaline / adrenaline Shift agonist vs effect curve to right. Higher concentrations of agonist can overcome competitive antagonist</p> <p><u>Irreversible or non competitive antagonist</u> Bind via covalent bonds or just binding so tightly to receptor so receptor unavailable for agonist. Duration of action of antagonist depend on rate of turnover of receptor-antagonist molecules. Reduces maximal effect of agonist but may not affect its EC50. eg phenoxybenzamine vs adrenaline</p> <div data-bbox="1041 555 1478 772"> </div>	<p>Must have good understanding of what happens with increasing agonist doses in both cases.</p>
<p>Question 2:</p>	<p>a) What are the proposed mechanisms of</p>	<p>a) Blocks Na channels thereby blocking sustained high frequency firing of neurones</p>	<p>Blocked</p>

Antagonists 2010-1

		CLINICAL	ESSENTIAL KNOWLEDGE
Question 1: Antagonist / agonists P14-16	<p>1. Describe the difference between a Competitive and an Irreversible antagonist</p> <p>2. Give an example of an antagonist?</p>	<p>Competitive - in fixed conc. of agonist, increasing conc. of antagonist will lead to progressively inhibited response, but an increasing agonist conc. can overcome to still evoke maximal response (agonist conc / effect curve shift to right) High comp. antagonist conc. prevent response completely if agonist conc. fixed</p> <p>Irreversible (Noncompetitive) - bind so tightly or covalently as to make receptor unavailable to agonist. Number of remaining receptors may then be too low to allow maximal response to occur regardless of agonist conc. (unless spare receptors) Length of effect of irrev. antagonist will reflect turnover of receptors involved rather than rate of elimination of antagonist</p> <p>Competitive: naloxone, flumazenil, Propranolol, isoprenaline, naltrexone, nalmeferne Irreversible: phenoxybenzamine, MAOI</p>	<p>Description visual or verbal</p> <p>1 example</p>

Antagonists 2008-1

<p>Competitive vs Irreversible Antagonists</p>	<p>What is an antagonist ?</p> <p>Explain the difference between a competitive and irreversible antagonist (Illustrate this with an example)</p>	<p>Receptor antagonists bind to receptors but do not activate them. The primary action of antagonists is to prevent agonists from activating receptors</p> <p>In the presence of a fixed concentration of agonist, increasing concentrations of a reversible competitive antagonist progressively inhibit the agonist response; high antagonist concentrations prevent response completely. eg Propranolol and Noradrenaline</p> <p>Irreversible antagonists bind to the receptor either by forming a covalent bond with the receptor or by binding so tightly that the receptor is unavailable for binding of the agonist eg Phenoxybenzamine vs adrenaline</p> <div data-bbox="981 518 1384 651"> </div> <p>Changes in agonist concentration-effect curves produced by a competitive antagonist (Panel A) or by an irreversible antagonist (Panel B). In the presence of a competitive antagonist, higher concentrations of agonist are required to produce a given effect; thus the agonist concentration (C') required for a given effect in the presence of concentration $[I]$ of an antagonist is shifted to the right, as shown. High agonist concentrations can overcome inhibition by a competitive antagonist. This is not the case with an irreversible (or noncompetitive) antagonist, which reduces the maximal effect the agonist can achieve, although it may not change its EC_{50}.</p> <p>Pass Be able to distinguish between competitive and irreversible antagonist</p>	
---	--	--	--

Antagonists 2003-2

Pharm Session 2 Topics	Questions	Essential knowledge	Comments	Pass / Fail (Score)
Antagonist/ Agonist/ Partial agonist	<p>1. How does an irreversible antagonist alter the concentration effect curve for a drug? (Draw the curve to demonstrate.) (What happens to EC50?)</p> <p>2. How does this compare to a competitive antagonist? (Draw the curve to demonstrate.)</p> <p>3. Which of these does the curve for a partial agonist most resemble?</p>	<p>Draws curve for agonist alone. Draws curve for agonist plus irreversible antagonist. Reduced maximum effect. EC50 may not alter.</p> <p>Draws curve shifted to right, with EC50 increased and maximum effect not changed.</p> <p>Irreversible antagonist.</p>	<p>Ask about maximum effect and EC50.</p> <p>Ask about maximum effect and EC 50.</p> <p>Bold items required to pass.</p>	

Efficacy and Potency 2017-1-A

Stem: Moving onto Pharmacology. He is given morphine for his pain.

Question 5

Potency and efficacy

Subject:
Pharm

LOA: 1

a) Can you define potency?

Prompt:

What does ED50 or EC50 refer to?

b) Can you define efficacy?

c) Show the difference between efficacy and potency by drawing graded dose response curves.

Optional if time allows
Compare the potency of morphine to fentanyl.

a) The **amount of drug required to produce an effect** of certain intensity.

Refers to the concentration (EC50) or dose (ED50) of a drug required to produce 50% of that drug's maximal effect. Dependent on affinity of drug for receptor and number of receptors available.

b) **Maximal effect a drug can produce** when all receptors are occupied, irrespective of conc required to produce that response (or irrespective of dose). Determined by the drug's mode of interactions with receptors or by characteristics of the receptor-effector system involved.

c) A and B have similar potency. A&B are more potent than C which is more potent than D for mild to moderate responses/effects.
A, C & D have similar efficacy and greater efficacy than B.
B is a partial agonist (producing less than full response despite full receptor occupancy)

Fentanyl 100x more potent. 0.1mg fentanyl = 10mg morphine

Refers to amount/conc required for a given effect.

Bold to pass

Bold to pass

Draw graph, & explain, correct axes






FIGURE 2-15 Graded dose-response curves for four drugs, illustrating different pharmacologic potencies and different maximal efficacies. (See text.)


Efficacy and Potency 2013-1

TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1: POTENCY & EFFICACY LOA: 1	<p>Define "potency".</p> <p>How is this different to Efficacy?</p> <p>Draw a concentration-response curve showing 2 drugs with the same potency but different efficacy.</p>	<p>Potency refers to the affinity or attraction between an agonist and its receptor. It reflects the dose axis of dose response curves. A measure of drug potency is the EC_{50} – the conc'n/dose req'd to produce 50% of maximal response.</p> <p>Efficacy is the maximal response that a drug (agonist) can produce (E_{max}) when all receptors are occupied, irrespective of the concentration required to produce that response. Efficacy determines a drugs clinical effectiveness and reflects the response axis</p>  <p>X and Z have similar efficacies, X and Y have similar potencies; X and Y are more potent than Z</p>	<p>Be able to explain potency and efficacy</p>


Efficacy and Potency 2010-2

<p>1.</p> <p>a. With regard to drugs, what is "potency".</p> <p>b. How is this different to Efficacy?</p> <p>c. Draw a concentration-response curve showing 2 drugs with the same potency but different efficacy.</p>	<p>Potency refers to the affinity or attraction between an agonist and its receptor.</p> <p>A good measure of drug potency is the EC_{50} – the concentration that produces 50% of the maximal response.</p> <p>Efficacy is the maximal response that a drug (agonist) can produce (E_{max}) when all receptors are occupied, irrespective of the concentration required to produce that response.</p> 	<p>Demonstrate understanding of efficacy and potency.</p>
---	--	---

Efficacy and Potency 2008-2

<p>Question 1: Efficacy and Potency</p>	<p>1. What is the difference between Efficacy and Potency?</p> <p>Prompt: You can draw a diagram if you like?</p>	<p>Potency: the concentration (EC_{50}) or dose (ED_{50}) of a drug required to produce 50% of that drug's maximal effect. Efficacy: the maximal effect that a drug exerts.</p> 	<p>Definitions to pass</p> <p>Examiner note: Drugs A and B are more potent than drugs C and D because of the relative positions of their dose-response curves along the dose axis. Drugs A, C, and D have equal maximal efficacy, while all have greater maximal efficacy than drug B.</p>
	<p>2. What factors affect a drug's efficacy?</p>	<p>Affinity of receptor for drug; the drug-receptor interaction . The route of administration, absorption, distribution through the body, and clearance from the blood or site of action</p>	<p>3 out of 6 to pass (NB not to do with potency)</p>

Efficacy and Potency 2007-1

<p>2.1 Efficacy and potency</p>	<p>Describe the difference between potency and efficacy</p>	<p>Potency = Amount causing the effect, higher potency has lower EC₅₀ or ED₅₀ Efficacy = Maximum effect of particular drug</p>	<p>DRUG RECEPTORS & PHARMACODYNAMICS / 29</p>  <p>The graph illustrates the relationship between drug concentration and response. The y-axis is labeled 'Response' and the x-axis is labeled 'Log concentration'. Four curves are shown: A, B, C, and D. Curves A, C, and D all reach the same maximum response level (efficacy), while curve B reaches a lower maximum. In terms of potency (the concentration required to achieve 50% of the maximum response), curve A is the most potent, followed by C, then D, and finally B is the least potent.</p>	<p>/2</p>
---------------------------------	---	---	--	-----------

Efficacy and Potency 2006-1

TOPIC	QUESTION	ESSENTIAL KNOWLEDGE	NOTES
Efficacy and potency	<p>Define potency?</p> <p>How does potency differ from efficacy for a given drug?</p> <p><i>PROMPT</i> What is meant by the term EC 50?</p>	<p>Measure of how much drug required for effect. Defined in terms of concentration or dose required to produce 50% of maximal effect (EC50, ED50)</p> <p>Efficacy is measure of maximum effect of particular drug</p> <p>DEFINITION +/- GRAPH</p>	<p>Well illustrated with graph (figure 2-18 in Katzung, p 28)</p>

Efficacy and Potency 2005-1

Efficacy and Potency	<p>What is meant by the term efficacy?</p> <p>How does efficacy differ from potency?</p> <p>What factors influence the potency of a drug?</p>	<p>a) Efficacy reflects the limit of the dose-response relation on the response axis. Determined by the drug's mode of interaction with receptors (eg agonists, partial agonists) or by characteristics of the receptor-effector system.</p> <p>b) Potency refers to the concentration (EC_{50}) or dose (ED_{50}) of a drug required to provide 50% of that drug's maximal effect. The clinical effectiveness of a drug depends not on its potency but on its maximal efficacy and its ability to reach its relevant receptors. In considering which of 2 drugs to prescribe, pick the one with the greatest efficacy. Potency can then determine the administered dose.</p> <p>(c) Potency is affected by the affinity of receptors for binding the drug, and the coupling efficiency.</p>
----------------------	---	---

Second Messengers 2010-1

<p>Question 1: Second messengers P21-26</p>	<p>1. What are the steps in activation of a second messenger?</p> <p>2. Give an example of a second messenger and the type of response it produces? <i>What about cAMP?</i></p>	<p>Method of transmembrane signalling Drug binds to a receptor on extracellular side plasma membrane Triggers activation of G protein on cytoplasmic side Activated G protein changes an enzyme or ion channel This changes concentration of intracellular second messenger which mediates a response</p> <p>cAMP via adenylate cyclase Mobilization of fat and carbohydrates Conservation of water by kidney Increase rate and contractility of heart Ca⁺⁺ regulation Adrenal hormone regulation, relaxation of smooth muscle Ca⁺⁺ and Phosphoinositides</p> <p>cGMP via transmembrane guanylyl cyclase (atrial natriuretic peptide) or nitric oxide which binds to a cytoplasmic guanylyl cyclase GTN, Na nitroprusside Inhibition of phosphodiesterase – increased cGMP eg sildenafil</p>	<p>Binding Transmembrane signal G protein Effector</p> <p>name 1 and some knowledge of a response</p>
---	---	--	---

Second Messengers 2008-1

<p>Second Messengers</p>	<p>In reference to drug action what is a second messenger?</p> <p>What steps are involved in the action of a drug via a second messenger ? (Prompt - Illustrate this with an example)</p>	<p>A chemical eg Ca^{++} or cAMP that converts receptor binding to end effect through the production of an active intracellular element.</p> <p>Extracellular ligand specifically detected by a cell-surface receptor. Receptor triggers the activation of a G protein located on the cytoplasmic face of the plasma membrane. Activated G protein changes the activity of an effector element (usually enzyme or ion channel) This element changes the concentration of the intracellular second messenger.</p> <p>Example cAMP - G_s stimulates adenylyl cyclase which converts intracellular ATP to cAMP which stimulates cAMP-dependent protein kinases. Ca, Phosphoinositides cGMP</p> <p>(Pass –understanding of the concept that there may be a secondary process producing drug effect and able to name at least 1 second messenger)</p>	
--------------------------	---	---	--

Second Messengers 2006-2

TOPIC	QUESTIONS	EXPECTED KNOWLEDGE	COMMENT
1. Second Messengers	<p>1. Describe the 3 major steps in a second messenger receptor system (3 FOR A PASS)</p> <p>2. Give 3 examples of ligands that work via a second messenger (3 FOR A PASS)</p>	<p>1. Cell surface receptor for an extracellular ligand</p> <p>2. Intracytoplasmic activation of a G-protein</p> <p>3. Activation of an effector (eg adenylate cyclase) with production of the 2nd messenger (eg cAMP)</p> <p>See table 2-1 p22</p>	

Second Messengers 2004-2

Second messenger	<p>What do you understand by the term second messenger ?</p> <p>Please describe the common steps in the mechanism of their activation</p> <p>(Explain the concept of spare receptors ?)</p>	<p>Reasonable example/understanding</p> <p>Ligand/receptor binding G protein Effector element changes second messenger concentration</p> <p>Bonus question</p>	
------------------	---	--	--

Second Messengers 2003-2

<p>Second messengers pp 21-5</p>	<p>1. What do you understand by the term 'second messenger'?</p> <p>2. Describe the common steps in the activation of second messengers?</p> <p>3. Can you give examples of second messengers?</p>	<p>A second messenger is an intracellular substance which has its concentration altered by a process initiated by an extracellular ligand. The second messenger then acts to initiate or facilitate an intracellular process.</p> <p>3 basic steps 1.Extracellular process [EC] 2.Transmembrane signalling system [TM] 3.Intracellular process[IC]</p> <p>Extracellular ligand [EC] Cell surface receptor activated via ligand detection[EC] G protein activation [TM] Concentration change of an effector element [enzyme or ion channel][TM] Change in second messenger concentration[IC] Second messenger action on a substrate or enzyme[IC] Response[IC]</p> <p>1.Cyclic AMP 2.Calcium and phosphoinositides 3.Cyclic GMP</p>	<p>Must give reasonable explanation / example</p> <p>To pass: Must indicate 2/3 basic steps and have a reasonable idea of the details of each step either generically or by example</p> <p>To pass:[At least 2/3 required]</p>
--------------------------------------	---	---	--

Signalling Mechanisms 2012-2

TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1 Signalling mechanisms LOA: 1	List the various molecular mechanisms of transmembrane signalling. Describe the function of the system involving G proteins	<ol style="list-style-type: none"> 1. Lipid soluble ligand crosses membrane and binds to intracellular receptor. 2. Transmembrane receptor protein with ligand binding to extracellular domain regulating intracellular enzymatic activity 3. Transmembrane receptor protein that binds and stimulates protein tyrosine kinase 4. Ligand-gated transmembrane ion channels 5. Transmembrane receptor protein, G protein, intracellular second messenger <p>Transmembrane signally system with 3 separate components. Extracellular ligand binds to specific cell surface receptor. This receptor then activates G protein located on cytoplasmic surface of membrane. Activated G protein changes activity of effector element (enzyme or ion channel) leading to a change in concentration of second messenger.</p>	Describe 3 mechanisms to pass Bold concepts to pass
	Give an example of a drug that acts via this system.	<p>B agonist: B adrenoreceptor, G_s protein, adenylycyclase, increased concentration cAMP.</p> <p>(other examples include glucagon, thyrotropin, histamine, serotonin, acetylcholine, opioids)</p>	Correct example to pass. Extra points for describing components

Spare Receptors 2010-1

	QUESTION	NOTES	ESSENTIAL KNOWLEDGE
Question 1: Spare receptors & their significance P13-4	<p>1. Define the term "spare receptor"</p> <p>2. What is the significance of spare receptors? <i>How is it related to the maximal response of a drug?</i> <i>What do the terms spare in number and temporal spareness mean?</i></p>	<p>Receptors "spare" if maximal biologic response possible at an agonist concentration that does not result in all available receptors being occupied. Describes concept of receptors "spare in number". Can also have spareness "temporally" if effects produced by binding last much longer than the time the agonist occupied the receptor</p> <p>Increasing the number of receptors coupled to an effector can allow lower concentrations of agonist to still produce a given proportion of maximal response - tissue thus more sensitive</p>	<p>Highlighted section concept</p> <p>concept</p>
Question 2:	1. Describe the mechanism of action of	Irreversible inhibition of	

Spare Receptors 2009-2

<p>Question 1:</p>	<p>(a) Draw and explain a Dose-Response curve for an agonist</p>		<p>Must demonstrate relationship of concentration to effect</p>
<p>Dose Response</p>	<p>(b) Show how this curve is altered in the presence of an irreversible (non-competitive) antagonist</p>	<div data-bbox="987 284 1552 555"> <p>Figure 2-3. Changes in agonist concentration-effect curves produced by a competitive antagonist (A) or by an irreversible antagonist (B). In the presence of a competitive antagonist, higher concentrations of agonist are required to produce a given effect; thus the agonist concentration (C') required for a given effect in the presence of concentration $[I]$ of an antagonist is shifted to the right, as shown. High agonist concentrations can overcome inhibition by a competitive antagonist. This is not the case with an irreversible (or noncompetitive) antagonist, which reduces the maximal effect the agonist can achieve, although it may not change its EC_{50}.</p> </div>	<p>Pass - Non-competitive antagonist has lower maximal effect</p>
	<p>(c) How does this differ from a competitive antagonist?</p>		<p>Pass – Higher conc. of agonist to produce similar effect</p>

Spare Receptors 2006-2

TOPIC	QUESTIONS	EXPECTED MINIMUM KNOWLEDGE FOR PASS	COMMENT
1. Dose - response	<p>What are “spare receptors”?</p> <p>Describe the 2 main mechanisms that account for “spare receptor” phenomenon?</p> <p>What is the effect on the dose-response curve of an agonist with increasing concentrations of an irreversible antagonist?</p>	<p>Receptors in excess of number required for maximal physiol effect</p> <p>Temporal – prolonged effect after transient binding Numerical- limited substrate with excess receptors</p> <p>Curve is shifted to the right with increasing agonist concentrations until eventually only a submaximal effect is achieved</p>	

Absorption 2005-2

TOPIC: Absorption of Drugs _____ **NUMBER: 1**

OPENING QUESTION	What is first pass metabolism?	COMMENTS
POINTS REQUIRED	<p>After absorption of an orally ingested drug, portal blood delivers drug to liver</p> <ul style="list-style-type: none"> • Metabolised in gut wall • Metabolised in portal blood • Metabolised by liver • Excreted into bile <p>before reaching systemic circulation</p> <p>ie Reduces bio-availability of a drug</p>	<p>Basic definition is pass</p> <p>Has to include some changes of drug</p>
PROMPTS		
SECOND QUESTION (if needed)	<p>How can you increase bioavailability?</p> <p>Give an example</p>	
POINTS REQUIRED	<p>1 Different route of administration</p> <p>IV</p> <p>IM / SC</p> <p>SL</p> <p>PR – low</p> <p>Still may have some first pass metabolism – only 50% bypasses liver</p> <p>Inhalational</p> <p>Transdermal</p>	Must talk about alternative routes
	<p>2 Depending on properties of drug</p> <p>Increase absorption</p> <p>Hydrophilic</p> <p>Lipophilic</p> <p>Actively pumped into gut</p> <p>Prodrug</p>	
PROMPTS	Apart fromwhat can also increase its bioavailability	
THIRD QUESTION (if needed)	Give an example	
PROMPTS		

Bioavailability 2014-1-D

Stem: You have a 25 yo man with a painful knee. He has received ibuprofen for analgesia. The first topic is PHARMACOLOGY .			
TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1 Bioavailability with particular reference to NSAIDs Subject: Pharm LOA: 1	(a) What is bioavailability?	(a) Fraction of unchanged drug reaching the systemic circulation following administration by any route	(a) Bold to pass
	(b) What factors affect bioavailability?	(b) 3 factors: Extent of absorption <ul style="list-style-type: none"> • Too hydrophilic or too lipophilic – decr. absorption • Reverse transporter associated with p-glycoprotein – pumps drug back to gut lumen – decr. absorption • Gut wall metabolism – decr. absorption First pass metabolism <ul style="list-style-type: none"> • Metabolism by liver before it reaches systemic circulation • Small additional effect if drug has biliary excretion Rate of absorption <ul style="list-style-type: none"> • Determined by site of administration and drug formulation 	(b) Bold with reasonable explanation of each
	(c) What is the bioavailability of ibuprofen?	(c) High - Weak organic acid – well absorbed rapidly . Minimal first pass metabolism	(c) Bold to pass

Bioavailability 2013-1

TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1: Bioavailability LOA: 2	What is bioavailability?	Fraction of unchanged drug reaching the systemic circulation following administration by any route.	Bold to pass
	What factors limit drug bioavailability following oral administration?	Extent of absorption: a) Property of the drug eg hydrophilic vs lipophilic b) Gut factors - reverse transporter pumps p-glycoprotein & gut wall metabolism First pass elimination- metabolism by liver before reaching systemic circulation or small effect biliary excretion	Bold to pass
	How can you overcome the effects of high first pass metabolism?	Change route of administration to sublingual, transdermal eg GTN, rectal, inhalation, IV, IM Increase dose Use pro-drugs	Bold

Bioavailability 2011-2

<p>Question 1 Bioavailability</p>	<p>a) Define bioavailability</p> <p>b) What factors affect bioavailability</p> <p>c) How can you overcome the effects of high first pass metabolism?</p>	<p>a) Fraction of unchanged drug reaching systemic circulation following administration by any route. AUC (conc-time) is a common measure of the extent of bioavailability.</p> <p>b) 3 Factors</p> <p>a) Extent of Absorption</p> <p>i) Too Hydrophilic or too lipophilic</p> <p>ii) Reverse transporter associated with P-glycoprotein – pumps drug back to gut lumen</p> <p>iii) Gut wall metabolism</p> <p>b) First Pass Elimination</p> <p>i) Metabolism by liver before it reaches systemic circulation</p> <p>ii) Small additional affect if drug has biliary excretion</p> <p>c) Rate of Absorption</p> <p>i) Determined by site of administration and drug formulation</p> <p>c) Change route of admin to: Sublingual, transdermal, rectal, inhalation, IV, IM ; increase dose</p>	<p>Bolded</p> <p>Bolded</p> <p>(Need 2 routes of admin)</p>
---	--	--	---

Bioavailability 2008-1

Bioavailability	<p>Define the term bioavailability</p> <p>What factors limit drug bioavailability following oral administration ?</p> <p>What methods of drug delivery are used to overcome bioavailability problems ?</p>	<p>Fraction of unchanged drug reaching the systemic circulation following administration by any route.</p> <p>(1) Extent of absorption (2) First-pass elimination (liver, gut)</p> <p>Alternative route – sublingual, rectal, transdermal parenteral</p> <p>Administration pro-drug, increased dose</p>	<p>Need close approximation of defn</p> <p>Identify both factors (prompt if necessary)</p> <p>Give one example of an alternative route</p>
-----------------	--	---	--

Bioavailability 2003-2

Session 3 Pharm Topics	Question/s	Essential knowledge required	Notes on Candidate	Pass /Fail
Bio- availability	1. Define bioavailability.	The fraction of unchanged drug reaching the systemic circulation following administration by any route.	All	
	2. What are the reasons why an orally administered drug might have less than 100% bioavailability?	Imperfect absorption First pass effect Degradation by bugs in the gut	Absorption, first pass required	
	3. What factors contribute to first pass elimination?	Hepatic metabolism Hepatic excretion Gut wall metabolism Portal blood metabolism	Require hepatic metabolism	
	4. What routes of administration other than parenteral can be used to avoid first pass metabolism?	Transmucosal Transdermal Rectal	Two required	

Biotransformation 2014-2-D

Stem: An elderly woman is brought to your ED hypothermic and unconscious. She is intubated. Commencing with pharmacology			
TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1 Biotransformation – Phase 1 and 2 reactions with an emphasis on Suxamethonium (Chp 4) Subject: Pharm LOA: 1	What is drug biotransformation?	Drug metabolism to allow drugs to become inactive or by increasing excretion by making them more hydrophilic, or by metabolising them to less active agent.	Bold
	Describe phase 1 and phase 2 reactions?	Phase 1 – unmasking functional group (-OH, -NH ₂ , -SH) to become more polar metabolite. Includes oxidation, deamination, hydrolysis, reductions Phase 2- conjugation with endogenous substrate to become highly polar conjugate	Bold
	How is Suxamethonium metabolised?	Rapid phase 1 hydrolysis by butyrylcholinesterase and pseudocholinesterase in liver and plasma Genetically deficient in BCHE so slowed metabolism	One of the bold
	Why may a patient have a prolonged paralysis following Sux		

45

Biotransformation 2012-1

TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1: LOA: 1 DIFFERENCES IN DRUG METABOLISM	What factors determine the difference in drug metabolism between individuals?	Genetic – enzyme level differences Diet – induce / inhibit enzymes Environmental – exposure to enzyme inducers Age – extremes have decreased enzyme activity or decreased levels of cofactors Sex – increased metabolic rate in males Drug-drug interactions – enzyme induction or inhibition, substrate competition Disease states - hepatic, pulmonary, cardiac, thyroid, inflammatory Liver size & function Circadian rhythm Body temperature	3 of 4 bold to pass
	What is meant by “enzyme induction”? <i>Prompt: What effect does it have on metabolism?</i> <i>Prompt: What effect does this have on the pharmacological action of the drug?</i>	Drug causes an increased rate of synthesis or decreased rate of degradation of enzyme causing: accelerated substrate metabolism decreased pharmacological action of the inducer or a co-administered drug.	Bold to pass

Biotransformation 2011-1

<p>Drug metabolism</p>	<p>Describe Phase 1 and Phase 2 reactions in drug metabolism.</p> <p>Prompt 1: What are some of the biochemical reactions that characterize phase 1 reactions? (Oxidation, reduction, hydrolysis)</p> <p>Prompt 2: How does phase 2 reactions enhance the excretion of a drug?</p>	<p>Process of chemical modification of a drug leading to more hydrophilic, more polar, readily excreted compound.</p> <p>Phase 1 (Functionalization) reactions: converts parent drug to more polar often inactive metabolite – process of oxidation, reduction, hydrolysis where polar functional group (OH, N H₂,SH) is introduced- majority reaction via cytochrome P450 enzymes.</p> <p>Phase 2 (Conjugation) reactions: metabolites combine with endogenous glucuronic a, sulphate, acetylcoenzyme A or glutathione to form more polar metabolite- reactions catalysed by different transferase enzymes.</p> <p>Note: Phase 1&2 can occur alone, sequentially or simultaneously. Metabolites can be more active or toxic than the parent drugs.</p>	<p>Pass: Need basic understanding of in general “metabolise to more polar and excretable compounds”</p> <p>Phase 1 1 example: (oxidation, reduction, hydrolysis) CYP450</p> <p>Phase 2 1 example: Conjugation to form more polar compound+ one example of the endogenous substances</p>
-------------------------------	--	--	---

Biotransformation 2009-2

TOPIC	QUESTION	ESSENTIAL KNOWLEDGE	NOTES
Question 1: Drug Biotransformation	(a) What are the sites of drug biotransformation? (Prompt – Which is the major?)	Liver - GIT - lung - skin - kidneys	Must get Liver and two others
	(b) What is a Phase 1 biotransformation reaction?	Conversion of a parent drug to a more polar / water soluble form by the adding or unmasking of a functional group , most commonly by oxidation but also by reduction or hydrolysis. The hepatic CYP (P450) enzymes are responsible for the majority of these reactions.	Must mention more polar or water soluble & oxidation
	(c) What is meant by enzyme induction , in liver biotransformation?	Repeated administration of a substrate brings about either enhanced enzyme synthesis or reduced enzyme degradation causing increased metabolism of the substrate	Must mention enzyme more active , therefore increased metabolism and reduced drug action (2 of 3 bolds to pass)

Biotransformation 2005-2

TOPIC: Biotransformation _____ **NUMBER: 1**

OPENING QUESTION	With respect to the biotransformation of drugs, please distinguish between Phase I and Phase II reactions.	COMMENTS
POINTS REQUIRED	1 Phase I convert the parent drug to a more polar metabolite by introducing or unmasking functional groups such as -OH, -NH ₂ , -SH.	Pass if definitions correct
	2 Phase I examples: Oxidations including cytochrome p450 dependent and independent, deaminations, desulfurations, dealkylations, dehydrogenations, Reductions, Hydrolysis.	
	3 Phase II involves conjugation in an endogenous substrate to form a highly polar conjugate.	
	4 Phase II reactions include glucuronidation, acetylation, sulfation, methylation, glutathione conjugation.	
	5 Both types of reactions result in more polar compounds that are more amenable to urinary excretion.	
PROMPTS		
SECOND QUESTION (if needed)	Does Biotransformation generally result in more or less active metabolites?	
POINTS REQUIRED	Usually less active (detoxification) may frequently result in metabolites with residual pharmacological activity or even enhanced activity (activation).	Must know this and give at least one example
PROMPTS	Please give some examples	

Biotransformation 2003-1

QUEST 1. Biotransformation

FIRST QUESTION	What do you understand by biotransformation	
	<p>Metabolism transforms lipophilic to more polar, more excretable products</p> <p>Phase I reaction – converts parent drug to more polar often inactive metabolite – process of oxidation, reduction, hydrolysis where functional group (OH, N H₂, SH) is introduced or unmasked – polar metabolites are readily excreted</p> <p>Less polar metabolites combine with glucuronic a, sulfuric a, acetic a or amino a to form polar metabolite = conjugation = Phase II reaction</p>	
SECOND QUESTION	Where does biotransformation occur?	
	<p>Between absorption and renal elimination</p> <p>Liver principal organ</p> <p>Intestine – clonazepam, chlorpromazine</p> <p>Gastric acid – penicillin</p> <p>Digestive enzymes – insulin</p> <p>Enzymes in wall of intestine – sympathy, catecholam.</p>	Liver + one other

Clearance 2017-2-C

Stem: A 35-year-old man presents with severe pain in his knee following a twisting injury at football. He is given analgesia at triage. Starting with Pharmacology

TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1 Drug clearance Subject: Pharmacology LOA: 1 <i>Katzung 13th</i> <i>pp 42-46</i>	<p>What is drug clearance?</p> <p>What factors affect clearance?</p> <p>What is the difference between capacity limited and flow dependent drug elimination?</p> <p>(prompt – what are the differences in elimination kinetics?)</p>	<p>Measure of the ability of the body to eliminate a drug. Rate of elimination in relation to the concentration OR Vol of plasma cleared of a drug per unit time.</p> <p>Concentration – dose/ bioavailability Elimination – specific organ function /blood flow /protein binding Major sites of elimination are kidneys and liver – therefore factors that affect these organs function and blood flow will have most effect</p> <p>Capacity limited – is saturable (zero order) e.g. aspirin, phenytoin, ethanol (so clearance varies depending on drug concentration).</p> <p>Flow dependent – is non-saturable (1st order) – most of drug is cleared on 1st pass of blood through an organ, so elimination depends on the rate of drug delivery to the organ - and hence on blood flow. Plasma protein binding and blood cell partitioning may also play a small role. e.g. Amitriptyline / imipramine / Labetalol / Lig/ Morphine / Verapamil</p>	<p>Reasonable definition concept of rate over time</p> <p>One factor for each element</p> <p>Bold</p>

Clearance 2014-1-D

Stem: A 70 yo woman undergoes procedural sedation in ED for reduction of a wrist fracture. The first topic is PHARMACOLOGY .			
TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1 Clearance Definition, factors affecting, examples Subject: Pharmacology LOA: 1	(a) What is drug clearance?	(a) Clearance: <ul style="list-style-type: none"> • Measure of the ability of the body to eliminate a drug • Rate of elimination in relation to drug concentration • $CL = \text{rate of elimination} / \text{concentration}$ 	(a) Reasonable definition to pass
	(b) What factors affect drug clearance?	<ul style="list-style-type: none"> • Concentration - Dose & Bioavailability • Elimination - specific organ function / blood flow & protein binding • Major sites of elimination are kidneys and liver – therefore factors that affect these organs' function and blood flow will have most effect 	(b) One for each element
	(c) What is the difference between capacity-limited and flow-dependent drug elimination?	(c) Capacity-limited is saturable (zero order) Examples: aspirin, phenytoin, ethanol. Flow-dependent = non-saturable (1st order) (organ blood flow, protein binding) Examples: Alprenolol / amitriptyline / Imipramine / isoniazid / labetalol / lignocaine / Morphine / propoxyphene / propranolol / verapamil	(c) Bold to pass

Clearance 2012-2

TOPIC	QUESTIONS	KNOWLEDGE	NOTES
Question 1 Clearance-renal and hepatic	What is drug clearance?	Clearance predicts the rate of elimination in relation to drug concentration. CL=rate of elimination/concentration	Bold
LOA 1	Which organs are involved in drug clearance?	2 main organs are kidney and liver , others are blood, muscle, lung. CL systemic= CL liver + CL kidney + CL other	Bold
	What factors affect renal clearance?	Renal function, renal blood flow , plasma protein binding, ionization	Bold
	Please name drugs that are predominantly cleared by the kidneys?	ampicillin, gentamicin , vancomycin, digoxin, enalapril, metformin, lithium	At least bold plus 2 others- prompt: Any drugs that need dose changes in patients with poor renal function?

Clearance 2010-2

1. a. What is meant by Total Body Clearance” of a drug	Describes the ability of the body to eliminate a drug . It refers to the theoretical volume of plasma emptied of drug per unit time (usually L/h). Total body clearance reflects the sum of all clearance process including renal, hepatic and other .	Definition
b. Name 2 drugs that have a high hepatic clearance and explain why this is important.	Lignocaine, Morphine, Propranolol, Pethidine. Drugs with high hepatic elimination may only be suitable for parenteral administration or have significant dosing variations depending on the route of administration. PROMPT: How might it impact on route of administration	2 drugs Demonstrate understanding
c. What factors determine drug half-life	Volume of Distribution and Clearance ($t_{1/2} = 0.693 \times V_d / Cl$) Vd and clearance change with disease states - cardiac, hepatic and renal failure	Vd and clearance

Clearance 2009-2

Question 1: Drug Clearance	(a) What formula describes Drug Clearance ?	Ratio of rate of elimination of a drug to its concentration in blood / plasma or $CL = \frac{\text{Rate of elimination}}{\text{Conc}}$	Must get formula to pass
	(b) What is Flow Dependent Elimination ? (prompt if needed – High extraction)	For drugs that are readily cleared by their organ of elimination (high extraction ratio), the rate of elimination is dependent on rate of drug delivery to the organ – determined by blood flow and plasma protein binding. (Systemic $CL = CL_{\text{renal}} + CL_{\text{liver}} + CL_{\text{other}}$)	Must mention drug delivery / blood flow to pass.
	(c) Can you name any drugs that have Flow dependent elimination	Hepatic –lignocaine; propranolol; verapamil? morphine; pethidine	One example to pass

Clearance 2005-2

TOPIC: Drug metabolism & influence on dosing NUMBER: 1

OPENING QUESTION	Define drug clearance	Comments
POINTS REQUIRED	<p>1. Volume of plasma/blood cleared per unit time, or</p> <p>2. $CL = \frac{\text{Rate of elimination}}{\text{concentration}}$</p> <p>$CL_{\text{systemic}} = CL_{\text{renal}} + CL_{\text{liver}} + CL_{\text{other}}$</p>	Need to know either of the two
PROMPTS	Units of measurement of clearance	
SECOND QUESTION	What is the relationship between clearance and the dosing frequency of a drug?	
POINTS REQUIRED	<p>1. Knowing the clearance of a drug will allow the dosage to be worked out to achieve the target concentration. To maintain steady state, the dosing rate ('rate in') must equal the rate of elimination ('rate out')</p> <p>2. Maintenance dose needs to be adjusted for disease state which affect clearance eg renal failure.</p> <p>3. Dosing rates (mg/h) = Rate of elimination (steady state) = $CL \times \text{target conc.}$</p>	Need to know 2 out of 3
THIRD QUESTION	Please give an example of dosage adjustment for impaired clearance	
POINTS REQUIRED	Gentamicin, digoxin in renal failure. Loading dose not affected, maintenance dose reduced or dosage interval increased.	Need to give one example

CYP 450 2008-2

Question 1: P450 enzyme system	1. What is the role of the cytochrome P450 enzyme system?	<p>Part of biotransformation system to detoxify drugs/substrates</p> <p>Acts by oxidation (phase 1 reaction): one molecule of oxygen is consumed per molecule of substrate</p> <p>Makes substrates more polar – easier to excrete or conjugate (phase2).</p> <p>Located on smooth endoplasmic reticulum</p> <p>Acts on a large number of lipophilic substrates, low specificity</p> <p>Relies on two enzymes: cytochrome P450, CP450 reductase (plus oxygen, NADPH). CP450 is a hemo-protein – active in the oxidized -ferric state- Fe3+</p>	Bold to pass
	2. What is the mechanism of CP450 enzyme induction and give examples?	<p>Enhanced rate of synthesis - Reduced rate of degradation of CP450 enzyme</p> <p>Specific enzyme inducers eg:</p> <p>CYP/CP 450 2B1 - barbiturates</p> <p>CP 450 3A –steroids, macrolides, anticonvulsants</p> <p>CP 450 2E1 – isoniazid, chronic ethanol</p> <p>CP 450 1A1 – pollutants – aromatic hydrocarbons in tobacco smoke</p>	1 mechanism and 2 examples

CYP 450 2007-2

3.1 P450 (MS)	<p>What is the role of Cytochrome P450 in drug metabolism?</p> <p>What are the effects of oxidation on the drug?</p> <p>List the basic mechanisms by which Cytochrome P450 enzymes are induced.</p> <p>Give examples ? (1 each).</p>	<p>Transfers activated oxygen to the drug to form the oxidized metabolite of the drug</p> <ul style="list-style-type: none"> • More polar (2 of 3 to pass) • more easily excreted • May be inactivated • Enhancing the rate of synthesis (1 to pass) • Reducing the rate of degradation <p>Enhanced synthesis; Dexamethasone, Phenobarbital Reduced degradation; Clotrimoxazole, ethanol</p>		<p>Score</p> <p>/2</p>
---------------	--	--	--	------------------------

Elimination 2013-2-D


Stem: A 60 yr old woman presents with severe jaw pain following a dental extraction a month earlier and is given IV morphine. Commencing with Pharmacology:

TOPIC	QUESTIONS	KNOWLEDGE	NOTES
PHARMACOLOGY Question 1 LOA: 1	1. Define drug elimination half life Prompt: Is there a formula you can use?	Time required to change the amount of drug in the body by ½ during elimination $T_{1/2} = 0.7 \times V_d / \text{clearance}$ (0.7 approx log 2) 50% after 1, >90% after 4	Bold to pass
	2. How does knowledge of a drug's half life help us clinically?	Dosing regimens Decay afterdose/overdose Time to steady state after dose change	2 to pass
	3. What disease states cab affect elimination half-life?	Liver, renal, cardiac disease	one organ
	4. What disease state could affect the elimination half-life of morphine?	Liver, renal	one organ

Elimination 2012-1

TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1 LOA: 1 HALF LIFE	<p>Define drug elimination half life</p> <p>Is there a formula you can use? <i>Prompt: What factors affect half-life?</i> <i>Prompt: Can you explain what that means?</i></p> <p>How does knowledge of a drug's half life help us clinically?</p>	<p>Time required to change the amount of drug in the body by ½ during elimination $T_{1/2} = 0.7 \times V_d / \text{clearance}$ (0.7 approx log 2)</p> <p>Indicates time to steady state after dose change. 50% after 1, >90% after 4</p>	<p>Concept required</p> <p>Both bold to pass</p>

Elimination 2009-1

Question 1. Zero and First order kinetics	1. What is "First order elimination kinetics"?	<p>First order: A constant fraction/percentage of the drug is eliminated per unit time. Rate of elimination is proportional to the amount of drug in the body. $t_{1/2}$ constant. Most drugs eliminated this way (____)</p> <p><small>It should be understood that a drug is being eliminated at a constant rate only if the amount of drug in the body is large enough to saturate the elimination mechanism. If the amount of drug in the body is small, the rate of elimination will be proportional to the amount of drug in the body, and the kinetics will be zero order.</small></p> 	Definition to pass
	2. How is it different to zero order kinetics? (prompt – capacity-limited)	Zero order: a constant amount of drug is eliminated per unit time. Rate of elimination is constant and is independent of drug. There is capacity limited clearance or mechanisms have been saturated in overdose.	
	3. Give some examples of drugs with zero order kinetics?	Examples: Ethanol, phenytoin, salicylates, theophylline, and thiopentone (at high doses) (.....)	2 examples to pass

Elimination 2006-1

TOPIC	QUESTION	ESSENTIAL KNOWLEDGE	NOTES
Elimination kinetics	<p>What is meant by the term capacity limited elimination?</p> <p><i>Prompt "what is meant by the term zero order kinetics"</i></p> <p>Give some examples of drugs with zero order kinetics?</p>	<p>definition</p> <p>Phenytoin, Alcohol, aspirin</p> <p>2 of 3</p>	<p>Zero order kinetics; Saturable kinetics, non linear Michalis Menten</p> <p>Graph allowed</p>

First Pass Effect 2010-2

1. a. What routes of drug administration are there?	Enteral: Sublingual, buccal, oral, rectal Parenteral: SC, IM, IV, intrathecal, epidural Inhalational Topical	Enteral/oral + 3 non-enteral
b. What factors affect the rate of drug absorption from the small intestine?	Ionisation status of drug: alkaline Intestinal pH (7-8) favours absorption of un-ionised basic drugs Intestinal motility; increased motility lead to reduced transit time and drug absorption Gut surface area, blood flow, solubility of drug, formulation of drug PROMPT: What is a specific drug factor	Must mention drug factors and gut factors
c. What are potential disadvantages of rectal drug administration?	Erratic absorption because of rectal contents Local drug irritation Uncertainty of drug retention	1/3

First Pass Effect 2008-2

<p>Question 1: First Pass effect</p>	<p>1. What is first pass effect?</p> <p>Prompt "Can you define first pass effect?"</p> <p>2. How can the first pass effect be reduced?</p>	<p>After absorption of an orally ingested drug, portal blood delivers drug to liver. *Metabolised in gut wall. *Metabolised in portal blood. *Metabolised by liver. *Excreted into bile Fraction of unchanged drug reaching systemic circulation may be reduced. ie. Reduces bio-availability of a drug</p> <p>Different route of administration IV; IM/SC; Sublingual; Transdermal; PR – Still may have some first pass metabolism, only 50% bypasses liver; Inhalational (may have first pass effect in the lung). Intrathecal</p>	<p>Pass: basic definition</p> <p>Mention 4 alternative routes</p>
--	--	--	---

First Pass Effect 2007-2

2.1 First pass effect (BF)	What is the first pass effect?	<p>1 The reduction in the absorbed dose of a drug that reaches the systemic circulation (plus 2 or 3)</p> <p>2 <u>Relates to drugs administered orally</u> and to some extent rectally</p> <p>3 Results in reduced bioavailability</p> <p>Oral =? - rectal</p> <p>1 Liver metabolism. 2 Portal blood metabolism 3 Gut wall metabolism 4 Bile excretion</p> <p>1 $ER = CL_{liver} / Q$ (Q @ 90L/hr in normal 70kg person)</p>	Score
	<p>PROMPTS</p> <p>What factors reduce the amount of an orally administered drug reaching the systemic circulation?</p> <p>To which routes of drug administration is it important?</p> <p>By what mechanisms does the first pass effect occur? Prompt Any sites of metabolism other than the liver?</p> <p>What is the formula for the extraction ratio?</p>		

Half life 2009-1

Topic	Question	Answer	Notes
Question 1: Drug Half-life	1. What is the definition of drug half-life?	1. time to change amount of drug in body by one half during elim (or infusion) OR $t_{1/2} = (0.7 \times V_d) / \text{clearance}$	Either definition or formula
	2. What disease states can affect drug half life?	2. Factors affecting V_d : malnutrition, albumin levels, change in muscle mass or fat distribution, oedema, ascites, effusions Factors affecting CL: poor nutrition, renal disease, hepatic disease, heart disease(CO)	Need 2 V_d factors, and renal plus one other for CL

Half life 2006-2

TOPIC	QUESTIONS	EXPECTED KNOWLEDGE	COMMENT
1. Drug half-life	<p>What is the half-life of a drug?</p> <p>How may it be expressed in relation to other pharmacokinetic parameters?</p> <p>Give examples of factors that affect half-life</p>	<p>Time required to change the amount of drug in the body by one-half during elimination.</p> <p>$T_{1/2} \propto V_d / Cl$</p> <p>(1 example for V_d and Cl)</p>	

Phase 1 and Phase 1 Reactions 2007-1

<p>3.1 Phase I and II reactions</p>	<p>Describe Phase I and Phase II reactions:</p> <p>What organs are involved?</p>	<p>See diagram in text of process leading to hydrophilic, more polar, readily excreted compound</p> <p>Phase I makes more polar/reactive, Phase II conjugation with polar molecule</p> <p>Prompt: What are some of the biochemical reactions that characterize phase I reactions Oxidation, reduction, hydrolysis Systems eg: MFO such as P450, NADPH</p> <p>Liver, lung, skin, intestinal wall (must get 2)</p>	<p>CHAPTER 4</p> <p>Phase I and phase II reactions in drug biotransformation. Phase II reactions may also precede</p>
-------------------------------------	--	---	--

Routes of Administration 2007-2

<p>1.1 Routes of Drug administration (JT)</p>	<p>By what different routes can drugs be administered?</p> <p>Discuss the factors affecting absorption from the oral route</p> <p>Give examples of drug administration that bypass the first pass effect</p>	<p>IV, IM, SC, o, rectal, inhalations, transdermal (5 to pass)</p> <p>Incomplete absorption, gut bacteria metabolism (digoxin), too hydrophilic (atenolol), too lipophilic (acyclovir)</p> <p>Acid-base interactions (aspirin) co ingestants (First pass effect, GIT transit time) reverse transporter</p> <p>All injections, GTN (patches, spray and sublingual tabs), transdermal fentanyl, rectal (partial)</p>	<p>/2</p>
---	--	--	-----------

Volume of Distribution 2012-2

TOPIC	QUESTIONS	KNOWLEDGE (essential in bold)	NOTES
Question 1 Volume of distribution LOA: 1	Define the “volume of distribution” of a drug.	Defined as the volume in which the amount of drug in the body would need to be uniformly distributed to produce the observed concentration in blood, plasma or water. $V_d = \text{Amt drug in body} / C$	Pass: either definition or formula
	How is it possible for a drug to have a V_d of 2500L in an adult?	Higher concentrations in extra vascular tissues than in blood – e.g. lipid soluble (not homogeneously distributed)	Pass: either not homogeneously distributed or extra vascular tissue higher conc
	Give an example of a drug with a: - high V_d - low V_d	High: Morphine, chloroquine, digoxin, clonidine, fluoxetine, tricyclics, β blockers, diazepam, Low/approximating ECF/TBW: aspirin, frusemide, antibiotics (gentamicin, amoxicillin, cephalexin), tolbutamide, phenytoin, valproic acid, lithium, warfarin, theophylline, indomethacin, sulphamethoxazole.	One of each One of each
	What is the importance of V_d in the overdose situation PROMPT – for example (drug name)?	Drugs with large V_d (TCAs) cannot be dialyzed whereas drugs with a low V_d (ASA, lithium) can.	Bold – use these to prompt; should be able to designate “high” or “low” V_d to pass.

[illegible][illegible]

Volume of Distribution 2009-1

QUESTIONS	QUESTIONS	ESSENTIAL KNOWLEDGE	NOTES
Question 1: Volume of Distribution	1. Define the "Volume of Distribution" of a drug	The apparent volume that a drug would occupy if it was evenly distributed according to its measured concentration in blood, plasma or water. $V_d = \frac{\text{Amount of drug in body}}{\text{Concentration in plasma or blood}}$	Pass: either definition or formula
	2. Fluoxetine has a volume of distribution of 2500L/70kg. What does this mean?	Has higher concentration in extravascular tissues than in the vascular compartment. high lipid solubility	
	3. Give an example of a drug with a low volume of distribution	aspirin, NSAIDS, warfarin, most antibiotics, tolbutamide	
Question 2:	1. What are the effects of adrenaline on the blood	Vascular resistance	Pass: 2 effects

Volume of Distribution 2007-1

<p>1.1 Volume of distribution</p>	<p>Define the term “volume of distribution”</p> <p>How is it possible for a drug to have a VD of 1600L/70kg?</p> <p>Give me an example of a drug with a:</p> <ul style="list-style-type: none"> - high VD (>70L/70kg) - low VD (<50 L/70kg, approximating TBW or ECF volume) <p>If a drug is distributed in the TBW, what is its V_D</p>	<p>Amount of drug in body /concentration in blood or plasma</p> <p>Higher concentrations in extra vascular tissues than in blood – e.g. lipid soluble</p> <p>High (must get one of bold): Morphine, chloroquine, digoxin, clonidine, fluoxetine, tricyclics, β blockers, diazepam, Low/approximating ECF/TBW (must get one of bold): aspirin, frusemide, antibiotics (gentamicin, amoxicillin, cephalexin), tolbutamide, phenytoin, valproic acid, lithium, warfarin Bold (particular relevance to EM)– use these to prompt; should be able to designate “high” or “low” VD to pass.</p> <p>TBW: 0.6 L/kg or 42 L/70kg</p>	<p>/2</p>
-----------------------------------	---	---	-----------

Volume of Distribution 2006-1

TOPIC	QUESTION	ESSENTIAL KNOWLEDGE	NOTES
Volume of distribution	<p>Define volume of distribution?</p> <p>How can a drug have a Vd greater than total body water?</p> <p>Give an example?</p> <p>What are the patient factors that alter Vd?</p>	<p>Amount of drug in body / Concentration in blood (or plasma)</p> <p>Drugs with high conc in extravasc tissues</p> <p>Digoxin (500 l), Imipramine (1600 l), Chloroquine (13000 l)</p> <p>Age; disease states</p> <p>Weight; Fat distribution</p> <p>2 of above</p>	<p>"Apparent" volume</p> <p>Lots of Choices (Katzung p37-8)</p> <p>Fluoxetine, nortriptylline, verapamil</p> <p>Mostly a function of body weight, depending of drug may go up or down with age. Alcohol decreases with age, diazepam increases with age (Goodman)</p>

Volume of Distribution 2003-1

QUEST 1. Volume of distribution

FIRST QUESTION	What do you understand by volume of distribution	
	<p>Volume of distribution is the measure of the apparent space in the body available to contain the drug</p> <p>It relates the amount of drug in the body to the concentration of the drug in blood or plasma</p> <p>$V_d = \text{Amt drug in body} / C$</p> <p>Drugs with a high volume of distribution are very tightly bound by tissues compared with blood, so have a much higher concentration in extravascular tissue than in the vascular compartment. If the drug is tightly bound to plasma proteins and not tissues it has a small volume of distribution</p>	
SECOND QUESTION	What factors affect volume of distribution	
	<p>Drug properties – lipid solubility, pKa, pH, protein binding, blood flow</p> <p>Patient properties – age, gender, disease, body composition</p>	<p>2 each</p> <p>2 each</p>
THIRD QUESTION	What is the importance of V_d in the overdose situation PROMPT – for example?	
	Drugs with large V_d (TCAs) cannot be dialyzed whereas drugs with a small V_d (ASA, lithium) can	1